Oryzon Reports Response Rate for Iadademstat Combination in AML Study
Oryzon Genomics reported a response rate for an iadademstat combination in an AML study.
Related stories
North Media Reports Q3 Revenue of DKK 307.5 Million
M impact | EQUITY | Nov 04, 2026, 03:31 PM UTC
North Media Reports Q3 2026 Earnings Growth, Narrows Guidance
The company attributes earnings growth to Last Mile and narrows its 2026 guidance; the revised outlook is not specified.
M impact | EQUITY | Nov 04, 2026, 03:30 PM UTC
Shoals Technologies Group Reports Quarterly Results
Shoals Technologies Group reported results for the quarter ended September 30; no figures are provided.
M impact | EQUITY | Nov 04, 2026, 03:19 PM UTC
Kocaer Celik Reports Q3 Revenue of 7.6 Billion Lira
Q3 revenue was 7.6 billion lira, versus 7.7 billion lira a year earlier.
M impact | EQUITY | Nov 04, 2026, 03:19 PM UTC
Kocaer Celik Reports Q3 Net Profit of 220.8 Million Lira
Q3 net profit was 220.8 million lira, versus 35.0 million lira a year earlier.
M impact | EQUITY | Nov 04, 2026, 03:19 PM UTC
MLP Saglik Q3 Net Profit Rises to 2.2 Billion Lira
MLP Saglik reported Q3 net profit of 2.2 billion lira, versus 2.1 billion lira a year earlier.
M impact | EQUITY | Nov 04, 2026, 03:19 PM UTC